Chimeric Therapeutics Ltd has released a press release.
ADVENT-AML Phase 1B clinical trial open to enrolment
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- Chimeric receives $7.36M R&D tax incentive
- Positive in vitro data for CHM 1301 CAR NK cells
- 1st patient dosed in Phase 1b recurrent glioblastoma trial
- FDA clearance of IND for CHM 2101
- Entitlement Offer to raise approximately $10 million
Later from Chimeric Therapeutics
- Placement of Entitlement Offer Shortfall
- 1st patient treated in ADVENT-AML Phase 1b clinical trial
- Half Yearly Report and Accounts
- Clinical milestones for 2024 & 2023 successes highlighted
- Resignation of CEO and Managing Director
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics